The Digest efficacy trial tested a one capsule per-meal dosing regimen and will study fat, protein and carbohydrate absorption in cystic fibrosis patients with exocrine pancreatic insufficiency.
In parallel with the efficacy trial, Altus is conducting a long-term safety study to evaluate Trizytek following one year of open-label treatment.
Georges Gemayel, president and CEO of Altus, said: “Completing the last patient visit of the Phase III efficacy trial marks an important milestone in the development of Trizytek. This news confirms that we are on track to report top-line Trizytek efficacy data in the third quarter of 2008.”